Based on the key indicators related to Argenx NV's liquidity, profitability, solvency, and operating efficiency, argenx NV ADR is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At this time, Argenx NV's Liabilities And Stockholders Equity is fairly stable compared to the past year. Other Stockholder Equity is likely to rise to about 6.7 B in 2024, despite the fact that Current Deferred Revenue is likely to grow to (89.9 M). Key indicators impacting Argenx NV's financial strength include:
Investors should never underestimate Argenx NV's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Argenx NV's cash flow, debt, and profitability to make informed and accurate decisions about investing in argenx NV ADR.
Net Income
(309.81 Million)
Argenx
Select Account or Indicator
Market Cap
Working Capital
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Net Current Asset Value
Income Quality
Roe
Tangible Asset Value
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Sale Purchase Of Stock
Investments
Total Cashflows From Investing Activities
Change To Account Receivables
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change To Inventory
Net Borrowings
Issuance Of Capital Stock
Total Assets
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Intangible Assets
Common Stock
Short Long Term Debt Total
Other Current Liab
Other Assets
Common Stock Shares Outstanding
Inventory
Short Term Debt
Non Currrent Assets Other
Short Term Investments
Net Tangible Assets
Long Term Investments
Property Plant Equipment
Other Liab
Capital Lease Obligations
Non Current Liabilities Other
Net Invested Capital
Net Working Capital
Capital Stock
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Income From Continuing Ops
Cost Of Revenue
Net Income Applicable To Common Shares
Tax Provision
Net Interest Income
Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Argenx NV Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Argenx NV's financial statements are interrelated, with each one affecting the others. For example, an increase in Argenx NV's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Argenx NV's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of argenx NV ADR. Check Argenx NV's Beneish M Score to see the likelihood of Argenx NV's management manipulating its earnings.
Argenx NV Stock Summary
Argenx NV competes with Blueprint Medicines, Amylyx Pharmaceuticals, Day One, Terns Pharmaceuticals, and Apellis Pharmaceuticals. argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Ltd, Universit Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands. Argenx Se is traded on NASDAQ Exchange in the United States.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
Cash flow analysis captures how much money flows into and out of argenx NV ADR. It measures of how well Argenx is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Argenx NV brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Argenx had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Argenx NV has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
Comparative valuation techniques use various fundamental indicators to help in determining Argenx NV's current stock value. Our valuation model uses many indicators to compare Argenx NV value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Argenx NV competition to find correlations between indicators driving Argenx NV's intrinsic value. More Info.
argenx NV ADR is number one stock in return on equity category among its peers. It is rated second in return on asset category among its peers . At this time, Argenx NV's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Argenx NV's earnings, one of the primary drivers of an investment's value.
Argenx NV's Earnings Breakdown by Geography
argenx NV ADR Systematic Risk
Argenx NV's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Argenx NV volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on argenx NV ADR correlated with the market. If Beta is less than 0 Argenx NV generally moves in the opposite direction as compared to the market. If Argenx NV Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one argenx NV ADR is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Argenx NV is generally in the same direction as the market. If Beta > 1 Argenx NV moves generally in the same direction as, but more than the movement of the benchmark.
Argenx NV Thematic Clasifications
argenx NV ADR is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
Today, most investors in Argenx NV Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Argenx NV's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Argenx NV growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Argenx NV help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of argenx NV ADR. We use our internally-developed statistical techniques to arrive at the intrinsic value of argenx NV ADR based on widely used predictive technical indicators. In general, we focus on analyzing Argenx Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Argenx NV's daily price indicators and compare them against related drivers.
When running Argenx NV's price analysis, check to measure Argenx NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Argenx NV is operating at the current time. Most of Argenx NV's value examination focuses on studying past and present price action to predict the probability of Argenx NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Argenx NV's price. Additionally, you may evaluate how the addition of Argenx NV to your portfolios can decrease your overall portfolio volatility.